Ozempic Gastroparesis Settlement: Georgia Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Concern

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has empowered individuals to make informed decisions about their well-being, often by translating complex biomedical concepts into accessible knowledge. Within this broad framework, discussions of metabolic health and pharmaceutical interventions have naturally evolved, reflecting ongoing advances in therapeutic science. As public awareness has grown, so too has attention to the real-world implications of widely prescribed medications. One such area of emerging focus involves the intersection of diabetes and weight management treatments with gastrointestinal health. Specifically, the use of glucagon-like peptide-1 receptor agonists, such as Ozempic, has prompted careful examination of their potential side effect profiles. Among these, gastroparesis—a condition characterized by delayed gastric emptying—has become a subject of heightened interest for patients and healthcare providers alike. This transition from general health education to a more targeted concern is particularly relevant for individuals in Georgia who may have experienced adverse effects following Ozempic exposure.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and, in severe cases, lead to malnutrition, dehydration, and aspiration pneumonia. Ozempic (semaglutide) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for the management of type 2 diabetes. Its pharmacology involves slowing gastric emptying as part of its glucose-lowering mechanism, which contributes to its therapeutic effects but also underlies many gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Pathways and Clinical Evidence

Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which inhibits gastric motility and delays gastric emptying. This effect is dose-dependent and can persist even after discontinuation. A case report documented a patient on semaglutide who, despite holding the medication for 12 days, completing bowel preparation, and fasting from solids for 32 hours and clear liquids for 10 hours, still had a distended antrum containing fluid and particulate matter consistent with a full stomach on preoperative gastric point-of-care ultrasound (https://pubmed.ncbi.nlm.nih.gov/41573454/). Endoscopy confirmed substantial residual gastric contents exceeding 200 mL. The authors noted that standard fasting protocols may not ensure gastric emptying in patients on GLP-1 RA therapy, particularly during medication up-titration or in those with coexisting gastrointestinal motility disorders (https://pubmed.ncbi.nlm.nih.gov/41573454/). This case illustrates the potential for severe and prolonged gastroparesis even after drug cessation.

Risk Considerations and Legal Context for Georgia Patients

Risk considerations for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. While the prescribing information lists gastrointestinal adverse reactions, it does not explicitly warn of gastroparesis as a distinct condition. The reported adverse events include dyspepsia, gastroesophageal reflux disease, and gastritis, but the term 'gastroparesis' is not used (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may leave patients and healthcare providers unaware of the risk for delayed gastric emptying severe enough to cause aspiration or require surgical intervention. Settlement-related considerations for patients in Georgia who have developed gastroparesis after using Ozempic involve several factors. The timeline between exposure and documented harm is critical. In clinical trials, gastrointestinal adverse reactions occurred most frequently during dose escalation, but the case report demonstrates that harm can persist long after drug cessation (https://pubmed.ncbi.nlm.nih.gov/41573454/). Patients may need to establish a clear temporal relationship between starting Ozempic and the onset of gastroparesis symptoms, as well as document any diagnostic tests confirming delayed gastric emptying. The severity of harm, including hospitalizations, aspiration events, or need for feeding tubes, can influence settlement amounts. Additionally, the adequacy of informed consent and whether patients were warned about the possibility of gastroparesis may be relevant in legal claims. In summary, the evidence indicates that Ozempic can cause significant gastrointestinal adverse reactions, including delayed gastric emptying consistent with gastroparesis, which may persist after drug discontinuation. Patients in Georgia affected by this condition should consult with a qualified injury lawyer to evaluate their case based on the specific facts and applicable law.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its glucose-lowering mechanism. This effect is dose-dependent and can persist even after discontinuation, potentially leading to severe and prolonged gastroparesis.

What evidence supports the link between Ozempic and gastroparesis?

Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). A case report documented a patient with significant residual gastric contents despite standard fasting protocols (https://pubmed.ncbi.nlm.nih.gov/41573454/).

Are there adequate warnings about gastroparesis on Ozempic's label?

The prescribing information lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This may leave patients and providers unaware of the risk.

What should Georgia patients do if they developed gastroparesis after using Ozempic?

Patients should document the timeline of Ozempic use and symptom onset, obtain diagnostic confirmation of gastroparesis, and consult with a qualified injury lawyer to evaluate their case based on the specific facts and applicable law.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.